Global Protein Therapeutics Market Outlook 2020
Once a rarely used subset of medical treatments, protein therapies have now found application in a large number of medical conditions. Since the introduction of the first recombinant protein therapeutic, the human insulin, the protein therapeutics market has revolutionized tremendously. Due to its increased usage, the market holds huge potential for future growth and it is estimated that by the end of 2020, it may reach the mark of US$ 208 Billion. Furthermore, the launch of new products is also likely to propel the market growth.
According to our new research report, “Global Protein Therapeutics Market Outlook 2020”, a large number of existing and new market players are rigorously involved in developing monoclonal antibodies (mAbs). The mAbs segment accounts for the largest share in the current protein therapeutic products. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments, which includes insulin, EPO, interferon, G-CSF, human growth hormone, blood clotting factors and FSH.
The report takes into account all the important aspects of the global protein therapeutics market, and projects the market during the period 2013-2020. Some of the key aspects included in the report are the market share analysis of key players and the segmental analysis. The report also provides in depth analysis of various applications of the above mentioned protein therapeutics. The current as well as the future market prospects of the applications of major protein therapeutics is also provided in the report.
Through in-depth and careful analysis of the worldwide developments, we have observed that the US continues to hold a dominant position in the global protein therapeutics market, as the country provides a major proportion of the products’ sales. However, our team of researchers has come up with an analysis that the future landscape looks promising, with respect to major contribution from emerging economies, which can be attributed to increasing awareness among people and an increased healthcare expenditure owing to the increase in the disposable income.
The report also covers an advanced phase drug analysis. This chapter lists all the protein therapeutics of the major players, which are in the third phase of the clinical trial. This analysis will help the client in understanding the potential market for the future. It also helps understand the major segments, indications and players in Protein Therapeutics that will continue to rule the market.
The report also states market forces that would govern the market, the drivers for the market, the challenges encountered by the market players, and the opportunities that the new and existing market players could grab, thereby resulting in the growth of the market. Moreover, the report provides a summary of the recent trends that may have an impact on the future industry performance.
The report provides insight about the lucrativeness of the industry through Porter’s Five Forces Analysis. This analysis will help the industry players to understand the level of competition within an industry, and would assist in business strategy development.
At the end, the key players of the market have been enlisted. A brief business overview of every player has been provided along with its product portfolio. This is followed by the recent developments of the player that may impact the market in the future. Overall, the report will prove to be a complete source of knowledge, and analysis for clients and potential investors.
According to our new research report, “Global Protein Therapeutics Market Outlook 2020”, a large number of existing and new market players are rigorously involved in developing monoclonal antibodies (mAbs). The mAbs segment accounts for the largest share in the current protein therapeutic products. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments, which includes insulin, EPO, interferon, G-CSF, human growth hormone, blood clotting factors and FSH.
The report takes into account all the important aspects of the global protein therapeutics market, and projects the market during the period 2013-2020. Some of the key aspects included in the report are the market share analysis of key players and the segmental analysis. The report also provides in depth analysis of various applications of the above mentioned protein therapeutics. The current as well as the future market prospects of the applications of major protein therapeutics is also provided in the report.
Through in-depth and careful analysis of the worldwide developments, we have observed that the US continues to hold a dominant position in the global protein therapeutics market, as the country provides a major proportion of the products’ sales. However, our team of researchers has come up with an analysis that the future landscape looks promising, with respect to major contribution from emerging economies, which can be attributed to increasing awareness among people and an increased healthcare expenditure owing to the increase in the disposable income.
The report also covers an advanced phase drug analysis. This chapter lists all the protein therapeutics of the major players, which are in the third phase of the clinical trial. This analysis will help the client in understanding the potential market for the future. It also helps understand the major segments, indications and players in Protein Therapeutics that will continue to rule the market.
The report also states market forces that would govern the market, the drivers for the market, the challenges encountered by the market players, and the opportunities that the new and existing market players could grab, thereby resulting in the growth of the market. Moreover, the report provides a summary of the recent trends that may have an impact on the future industry performance.
The report provides insight about the lucrativeness of the industry through Porter’s Five Forces Analysis. This analysis will help the industry players to understand the level of competition within an industry, and would assist in business strategy development.
At the end, the key players of the market have been enlisted. A brief business overview of every player has been provided along with its product portfolio. This is followed by the recent developments of the player that may impact the market in the future. Overall, the report will prove to be a complete source of knowledge, and analysis for clients and potential investors.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. GLOBAL PROTEIN THERAPEUTICS MARKET
3.1 Protein Therapeutics Market vs Pharmaceutical Market
3.2 Current and Future Market Analysis to 2020
3.2.1 Market Segmentation
3.2.2 Market Dynamics
3.2.2.1 Drivers
3.2.2.1.1 Increasing Healthcare Expenditure in the Emerging Markets
3.2.2.1.2 Government Initiatives to Improve the Healthcare Services
3.2.2.1.3 Rising Prevalence of Chronic Diseases
3.2.2.1.4 Growing Geriatric Population
3.2.2.2 Challenges
3.2.2.2.1 High Cost of Production and Treatment
3.2.2.2.2 Competition from Biosimilars
3.2.2.2.3 Patent Expiry of Blockbuster Drugs
3.2.2.3 Opportunities
3.2.2.3.1 Potential for Bispecific Monoclonal Antibodies
3.2.2.3.2 Unmet Medical Needs in the Developing Countries
4. INDUSTRY PERFORMANCE
4.1 Monoclonal Antibodies (mAbs)
4.1.1 Scientific Insight
4.1.2 Current and Future Market Analysis to 2020
4.1.3 By Application
4.1.4 Key Geographical Markets
4.1.5 Key Players and Drugs
4.1.6 Recent Developments
4.2 Erythropoietin (EPO)
4.2.1 Scientific Insight
4.2.2 Current and Future Market Analysis to 2020
4.2.3 By Application
4.2.4 Key Geographical Markets
4.2.5 Key Players and Drugs
4.2.6 Recent Developments
4.3 Insulin
4.3.1 Scientific Insight
4.3.2 Current and Future Market Analysis to 2020
4.3.3 By Application
4.3.4 Key Geographical Markets
4.3.5 Key Players and Drugs
4.3.6 Recent Developments
4.4 Interferon (IFN)
4.4.1 Scientific Insight
4.4.2 Current and Future Market Analysis to 2020
4.4.3 By Application
4.4.4 Key Geographical Markets
4.4.5 Key Players and Drugs
4.4.6 Recent Developments
4.5 Human Growth Hormone (HGH)
4.5.1 Scientific Insight
4.5.2 Current and Future Market Analysis to 2020
4.5.3 Key Geographical Markets
4.5.4 Key Players and Drugs
4.5.5 Recent Developments
4.6 Blood Clotting Factor
4.6.1 Scientific Insight
4.6.2 Current and Future Market Analysis to 2020
4.6.3 By Factor Type
4.6.4 Key Geographical Markets
4.6.5 Key Players and Drugs
4.6.6 Recent Developments
4.7 Follicle Stimulating Hormone (FSH)
4.7.1 Scientific Insight
4.7.2 Current and Future Market Analysis to 2020
4.7.3 Key Players and Drugs
4.7.4 Recent Developments
4.8 Granulocyte Colony Stimulating Factor (G-CSF)
4.8.1 Scientific Insight
4.8.2 Current and Future Market Analysis to 2020
4.8.3 Key Geographical Markets
4.8.4 Key Players and Drugs
4.8.5 Recent Developments
5. ADVANCED PHASE DRUGS ANALYSIS
6. EMERGING MARKET TRENDS
6.1 Gaining Momentum: Strategic Activities among Players to Develop Novel Treatments
6.2 Effective Delivery Methods: Improving the Reach of Therapies
6.3 Players Investing Heavily in Multiple Sclerosis and Cancer Therapeutics
6.4 Increasing Focus on Development of Biobetters
7. PORTERS FIVE FORCES ANALYSIS
8. KEY PLAYERS
8.1 Johnson & Johnson
8.2 Biogen Idec Inc.
8.3 Eli Lilly & Company
8.4 Sanofi-Aventis
8.5 Merck Serono S.A.
8.6 Roche Group
8.7 Amgen Inc.
8.8 Pfizer
8.9 Abbott Laboratories
8.10 Novo Nordisk
2. RESEARCH METHODOLOGY
3. GLOBAL PROTEIN THERAPEUTICS MARKET
3.1 Protein Therapeutics Market vs Pharmaceutical Market
3.2 Current and Future Market Analysis to 2020
3.2.1 Market Segmentation
3.2.2 Market Dynamics
3.2.2.1 Drivers
3.2.2.1.1 Increasing Healthcare Expenditure in the Emerging Markets
3.2.2.1.2 Government Initiatives to Improve the Healthcare Services
3.2.2.1.3 Rising Prevalence of Chronic Diseases
3.2.2.1.4 Growing Geriatric Population
3.2.2.2 Challenges
3.2.2.2.1 High Cost of Production and Treatment
3.2.2.2.2 Competition from Biosimilars
3.2.2.2.3 Patent Expiry of Blockbuster Drugs
3.2.2.3 Opportunities
3.2.2.3.1 Potential for Bispecific Monoclonal Antibodies
3.2.2.3.2 Unmet Medical Needs in the Developing Countries
4. INDUSTRY PERFORMANCE
4.1 Monoclonal Antibodies (mAbs)
4.1.1 Scientific Insight
4.1.2 Current and Future Market Analysis to 2020
4.1.3 By Application
4.1.4 Key Geographical Markets
4.1.5 Key Players and Drugs
4.1.6 Recent Developments
4.2 Erythropoietin (EPO)
4.2.1 Scientific Insight
4.2.2 Current and Future Market Analysis to 2020
4.2.3 By Application
4.2.4 Key Geographical Markets
4.2.5 Key Players and Drugs
4.2.6 Recent Developments
4.3 Insulin
4.3.1 Scientific Insight
4.3.2 Current and Future Market Analysis to 2020
4.3.3 By Application
4.3.4 Key Geographical Markets
4.3.5 Key Players and Drugs
4.3.6 Recent Developments
4.4 Interferon (IFN)
4.4.1 Scientific Insight
4.4.2 Current and Future Market Analysis to 2020
4.4.3 By Application
4.4.4 Key Geographical Markets
4.4.5 Key Players and Drugs
4.4.6 Recent Developments
4.5 Human Growth Hormone (HGH)
4.5.1 Scientific Insight
4.5.2 Current and Future Market Analysis to 2020
4.5.3 Key Geographical Markets
4.5.4 Key Players and Drugs
4.5.5 Recent Developments
4.6 Blood Clotting Factor
4.6.1 Scientific Insight
4.6.2 Current and Future Market Analysis to 2020
4.6.3 By Factor Type
4.6.4 Key Geographical Markets
4.6.5 Key Players and Drugs
4.6.6 Recent Developments
4.7 Follicle Stimulating Hormone (FSH)
4.7.1 Scientific Insight
4.7.2 Current and Future Market Analysis to 2020
4.7.3 Key Players and Drugs
4.7.4 Recent Developments
4.8 Granulocyte Colony Stimulating Factor (G-CSF)
4.8.1 Scientific Insight
4.8.2 Current and Future Market Analysis to 2020
4.8.3 Key Geographical Markets
4.8.4 Key Players and Drugs
4.8.5 Recent Developments
5. ADVANCED PHASE DRUGS ANALYSIS
6. EMERGING MARKET TRENDS
6.1 Gaining Momentum: Strategic Activities among Players to Develop Novel Treatments
6.2 Effective Delivery Methods: Improving the Reach of Therapies
6.3 Players Investing Heavily in Multiple Sclerosis and Cancer Therapeutics
6.4 Increasing Focus on Development of Biobetters
7. PORTERS FIVE FORCES ANALYSIS
8. KEY PLAYERS
8.1 Johnson & Johnson
8.2 Biogen Idec Inc.
8.3 Eli Lilly & Company
8.4 Sanofi-Aventis
8.5 Merck Serono S.A.
8.6 Roche Group
8.7 Amgen Inc.
8.8 Pfizer
8.9 Abbott Laboratories
8.10 Novo Nordisk
LIST OF FIGURES:
Figure 3-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2014
Figure 3-2: Global - Protein Therapeutics Market (Billion US$), 2013-2020
Figure 3-3: Global - Protein Therapeutics Market by Segment (%), 2014
Figure 3-4: Global - Forecast for Protein Therapeutics Market by Segment (%), 2020
Figure 4-1: Global - Monoclonal Antibodies Market (Billion US$), 2013-2020
Figure 4-2: Global - Monoclonal Antibodies Market by Application (%), 2014
Figure 4-3: Global - Monoclonal Antibodies Application in Cancer Treatment (Billion US$), 2013-2020
Figure 4-4: Global - Monoclonal Antibodies Application in Rheumatoid Arthritis Treatment (Billion US$), 2013-2020
Figure 4-5: Global - Monoclonal Antibodies Application in Other Chronic Diseases Treatment (Billion US$), 2013-2020
Figure 4-6: US - Monoclonal Antibodies Market (Billion US$), 2013-2020
Figure 4-7: Europe - Monoclonal Antibodies Market (Billion US$), 2013-2020
Figure 4-8: Japan - Monoclonal Antibodies Market (Billion US$), 2013-2020
Figure 4-9: Global - Monoclonal Antibody Market by Key Players (%) (2014)
Figure 4-10: Global - Erythropoietin Market (Billion US$), 2012-2018
Figure 4-11: Global - Erythropoietin Market by Segment (%) (2014)
Figure 4-12: Global - Number of Patients on Dialysis (Million), 2014 & 2020
Figure 4-13: Global - Breakup of Patients on Dialysis by Region (%), 2014
Figure 4-14: Global - Number of New Cancer Cases (Million), 2012 & 2020
Figure 4-15: Global - Breakup of New Cancer Cases by Region (%), 2020
Figure 4-16: US - Erythropoietin Market (Billion US$), 2013-2020
Figure 4-17: Europe - Erythropoietin Market (Billion US$), 2013-2020
Figure 4-18: Global - Erythropoietin Market by Key Player (%), (2014)
Figure 4-19: Global - Insulin Market (Billion US$), 2013-2020
Figure 4-20: Global - Number of Diabetic Patients (Million), 2013 & 2035
Figure 4-21: US - Insulin Market (Billion US$), 2013-2020
Figure 4-22: Europe - Insulin Market (Billion US$), 2013-2020
Figure 4-23: Asia - Insulin Market (Billion US$), 2013-2020
Figure 4-24: Global - Insulin Market by Key Players (%) (2014)
Figure 4-25: Global - Insulin Market by Products (%)(2014)
Figure 4-26: Global - Interferon Market (Billion US$), 2013-2020
Figure 4-27: Global - Interferon Market by Segment (%) (2014)
Figure 4-28: Global - Interferon Alpha Market (Billion US$), 2012-2014
Figure 4-29: Global - Interferon Beta Market (Billion US$), 2012-2014
Figure 4-30: US - Interferon Market (Billion US$), 2013-2020
Figure 4-31: Europe - Interferon Market (Billion US$), 2013-2020
Figure 4-32: Global - Interferon Market by Key Player (%) (2014)
Figure 4-33: Global - Human Growth Hormone Market (Billion US$), 2013-2020
Figure 4-34: US - Human Growth Hormone Market (Billion US$), 2013-2020
Figure 4-35: Europe - Human Growth Hormone Market (Billion US$), 2013-2020
Figure 4-36: Global - Human Growth Hormone Market by Key Players (%) (2014)
Figure 4-37: Global - Blood Clotting Factor Market (Billion US$), 2013-2020
Figure 4-38: Global - Blood Clotting Factor Market by Segment (%) (2014)
Figure 4-39: Global - Blood Clotting Recombinant Factor VIII Market (Billion US$), 2013-2020
Figure 4-40: Global - Recombinant Blood Clotting Factor VII Market (Billion US$), 2013-2020
Figure 4-41: Global - Recombinant Blood Clotting Factor Market IX (Billion US$), 2013-2020
Figure 4-42: US - Blood Clotting Factor Market (Billion US$), 2013-2020
Figure 4-43: Europe - Blood Clotting Factor Market (Billion US$), 2013-2020
Figure 4-44: Global - Blood Clotting Factor Market by Key Players (%) (2014)
Figure 4-45: Global - Follicle Stimulating Hormone Market (Billion US$), 2013-2020
Figure 4-46: Global - Granulocyte Colony Stimulating Factor Market (Billion US$), 2013-2020
Figure 4-47: US - Granulocyte Colony-Stimulating Factor Market (Billion US$), 2013-2020
Figure 4-48: Europe - Granulocyte Colony-Stimulating Factor Market (Billion US$), 2013-2020
Figure 7-1: Porters Five Forces Analysis
Figure 3-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2014
Figure 3-2: Global - Protein Therapeutics Market (Billion US$), 2013-2020
Figure 3-3: Global - Protein Therapeutics Market by Segment (%), 2014
Figure 3-4: Global - Forecast for Protein Therapeutics Market by Segment (%), 2020
Figure 4-1: Global - Monoclonal Antibodies Market (Billion US$), 2013-2020
Figure 4-2: Global - Monoclonal Antibodies Market by Application (%), 2014
Figure 4-3: Global - Monoclonal Antibodies Application in Cancer Treatment (Billion US$), 2013-2020
Figure 4-4: Global - Monoclonal Antibodies Application in Rheumatoid Arthritis Treatment (Billion US$), 2013-2020
Figure 4-5: Global - Monoclonal Antibodies Application in Other Chronic Diseases Treatment (Billion US$), 2013-2020
Figure 4-6: US - Monoclonal Antibodies Market (Billion US$), 2013-2020
Figure 4-7: Europe - Monoclonal Antibodies Market (Billion US$), 2013-2020
Figure 4-8: Japan - Monoclonal Antibodies Market (Billion US$), 2013-2020
Figure 4-9: Global - Monoclonal Antibody Market by Key Players (%) (2014)
Figure 4-10: Global - Erythropoietin Market (Billion US$), 2012-2018
Figure 4-11: Global - Erythropoietin Market by Segment (%) (2014)
Figure 4-12: Global - Number of Patients on Dialysis (Million), 2014 & 2020
Figure 4-13: Global - Breakup of Patients on Dialysis by Region (%), 2014
Figure 4-14: Global - Number of New Cancer Cases (Million), 2012 & 2020
Figure 4-15: Global - Breakup of New Cancer Cases by Region (%), 2020
Figure 4-16: US - Erythropoietin Market (Billion US$), 2013-2020
Figure 4-17: Europe - Erythropoietin Market (Billion US$), 2013-2020
Figure 4-18: Global - Erythropoietin Market by Key Player (%), (2014)
Figure 4-19: Global - Insulin Market (Billion US$), 2013-2020
Figure 4-20: Global - Number of Diabetic Patients (Million), 2013 & 2035
Figure 4-21: US - Insulin Market (Billion US$), 2013-2020
Figure 4-22: Europe - Insulin Market (Billion US$), 2013-2020
Figure 4-23: Asia - Insulin Market (Billion US$), 2013-2020
Figure 4-24: Global - Insulin Market by Key Players (%) (2014)
Figure 4-25: Global - Insulin Market by Products (%)(2014)
Figure 4-26: Global - Interferon Market (Billion US$), 2013-2020
Figure 4-27: Global - Interferon Market by Segment (%) (2014)
Figure 4-28: Global - Interferon Alpha Market (Billion US$), 2012-2014
Figure 4-29: Global - Interferon Beta Market (Billion US$), 2012-2014
Figure 4-30: US - Interferon Market (Billion US$), 2013-2020
Figure 4-31: Europe - Interferon Market (Billion US$), 2013-2020
Figure 4-32: Global - Interferon Market by Key Player (%) (2014)
Figure 4-33: Global - Human Growth Hormone Market (Billion US$), 2013-2020
Figure 4-34: US - Human Growth Hormone Market (Billion US$), 2013-2020
Figure 4-35: Europe - Human Growth Hormone Market (Billion US$), 2013-2020
Figure 4-36: Global - Human Growth Hormone Market by Key Players (%) (2014)
Figure 4-37: Global - Blood Clotting Factor Market (Billion US$), 2013-2020
Figure 4-38: Global - Blood Clotting Factor Market by Segment (%) (2014)
Figure 4-39: Global - Blood Clotting Recombinant Factor VIII Market (Billion US$), 2013-2020
Figure 4-40: Global - Recombinant Blood Clotting Factor VII Market (Billion US$), 2013-2020
Figure 4-41: Global - Recombinant Blood Clotting Factor Market IX (Billion US$), 2013-2020
Figure 4-42: US - Blood Clotting Factor Market (Billion US$), 2013-2020
Figure 4-43: Europe - Blood Clotting Factor Market (Billion US$), 2013-2020
Figure 4-44: Global - Blood Clotting Factor Market by Key Players (%) (2014)
Figure 4-45: Global - Follicle Stimulating Hormone Market (Billion US$), 2013-2020
Figure 4-46: Global - Granulocyte Colony Stimulating Factor Market (Billion US$), 2013-2020
Figure 4-47: US - Granulocyte Colony-Stimulating Factor Market (Billion US$), 2013-2020
Figure 4-48: Europe - Granulocyte Colony-Stimulating Factor Market (Billion US$), 2013-2020
Figure 7-1: Porters Five Forces Analysis
LIST OF TABLES:
Table 3-1: US & Europe - Major Drugs Patent Expiry in Protein Therapeutics Market
Table 4-1: Global - Key Players and Drugs in Monoclonal Antibody Market (Billion US$), 2012-2014
Table 4-2: Global - Key Players and Drugs in Erythropoietin Alfa Market (Billion US$), 2012-2014
Table 4-3: Global - Key Players and Drugs in Erythropoietin Beta Market (Billion US$), 2012-2014
Table 4-4: Global - Key Players and Drugs in Darbepoetin Market (Billion US$), 2012-2014
Table 4-5: US - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035f
Table 4-6: Europe - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035
Table 4-7: China - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035f
Table 4-8: Global - Key Players and Drugs in Interferon Alpha Market (Billion US$), 2012-2014
Table 4-9: Global - Key Players and Drugs in Interferon Beta Market (Billion US$), 2012-2014
Table 4-10: Global - Key Players and Drugs in Human Growth Hormone Market (Billion US$), 2012-2014
Table 4-11: Global - Key Players and Drugs in Blood Clotting Factor Market (Billion US$), 2012-2014
Table 4-12: Global - Key Players and Drugs in Follicle Stimulating Hormone Market (Billion US$), 2012-2014
Table 4-13: Global - Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Billion US$), 2012-2014
Table 5-1: Advanced Phase Protein Therapeutics
Table 8-1: Johnson & Johnson - Key Products in Protein Therapeutics
Table 8-2: Biogen - Key Products in Protein Therapeutics
Table 8-3: Eli Lilly - Key Products in Protein Therapeutics
Table 8-4: Sanofi-Aventis - Key Products in Protein Therapeutics
Table 8-5: Merck Serono - Key Products in Protein Therapeutics
Table 8-6: Roche - Key Products in Protein Therapeutics
Table 8-7: Amgen Inc. - Key Products in Protein Therapeutics
Table 8-8: Pfizer Inc. - Key Products in Protein Therapeutics
Table 8-9: Abbott Laboratories - Key Products in Protein Therapeutics
Table 8-10: Novo Nordisk - Key Products in Protein Therapeutics
Table 3-1: US & Europe - Major Drugs Patent Expiry in Protein Therapeutics Market
Table 4-1: Global - Key Players and Drugs in Monoclonal Antibody Market (Billion US$), 2012-2014
Table 4-2: Global - Key Players and Drugs in Erythropoietin Alfa Market (Billion US$), 2012-2014
Table 4-3: Global - Key Players and Drugs in Erythropoietin Beta Market (Billion US$), 2012-2014
Table 4-4: Global - Key Players and Drugs in Darbepoetin Market (Billion US$), 2012-2014
Table 4-5: US - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035f
Table 4-6: Europe - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035
Table 4-7: China - Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2035f
Table 4-8: Global - Key Players and Drugs in Interferon Alpha Market (Billion US$), 2012-2014
Table 4-9: Global - Key Players and Drugs in Interferon Beta Market (Billion US$), 2012-2014
Table 4-10: Global - Key Players and Drugs in Human Growth Hormone Market (Billion US$), 2012-2014
Table 4-11: Global - Key Players and Drugs in Blood Clotting Factor Market (Billion US$), 2012-2014
Table 4-12: Global - Key Players and Drugs in Follicle Stimulating Hormone Market (Billion US$), 2012-2014
Table 4-13: Global - Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Billion US$), 2012-2014
Table 5-1: Advanced Phase Protein Therapeutics
Table 8-1: Johnson & Johnson - Key Products in Protein Therapeutics
Table 8-2: Biogen - Key Products in Protein Therapeutics
Table 8-3: Eli Lilly - Key Products in Protein Therapeutics
Table 8-4: Sanofi-Aventis - Key Products in Protein Therapeutics
Table 8-5: Merck Serono - Key Products in Protein Therapeutics
Table 8-6: Roche - Key Products in Protein Therapeutics
Table 8-7: Amgen Inc. - Key Products in Protein Therapeutics
Table 8-8: Pfizer Inc. - Key Products in Protein Therapeutics
Table 8-9: Abbott Laboratories - Key Products in Protein Therapeutics
Table 8-10: Novo Nordisk - Key Products in Protein Therapeutics
